Dr. Hidalgo Medina on the Rationale for Using Patient-Derived Organoids in Pancreatic Cancer
May 2nd 2020Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.
Dr. Tagawa on Ongoing Research With 225Ac-J591 in mCRPC
April 17th 2020Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, and associate attending physician, Weill Cornell Medical Center/NewYork-Presbyterian Hospital, discusses ongoing research with 225Ac-J591 in metastatic castration-resistant prostate cancer.
PSMA-Targeted Radionuclide Therapy Shows Preliminary Activity in mCRPC
April 10th 2020Scott T. Tagawa, MD, MS, discusses the results of the phase I dose-escalation trial, the advantages of using an alpha emitter and a monoclonal antibody, and the possibility of combining the modality with other classes of agents in prostate cancer.
Talking Tumors: Turning to Liquid Biopsies and Immunotherapy in Lung Cancer
February 27th 2020Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.
Talking Tumors: Weill Cornell Medicine Experts Walk Through Challenging Breast Cancer Cases
December 18th 2019Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.